India, Dec. 18 -- Sun Pharmaceutical Industries on Thursday said the US Food and Drug Administration (USFDA) has classified its Baska manufacturing facility in Gujarat under the Official Action Indicated (OAI) category following a recent inspection.
The USFDA had inspected the facility between September 8 and September 19, 2025. Subsequently, the regulator determined the inspection outcome as OAI, the Mumbai-based drugmaker said in a regulatory filing.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....